Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 13/20 | 0.74 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.53 |
| ▸ | MMP13 | P45452 | 2/20 | 0.53 |
| ▸ | SCD | O00767 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL214421 | 0.89 | HDAC1 (0.82) | HDAC1HDAC2HDAC3HDAC8NCOR2 | |
| SCHEMBL210213 | 0.86 | HDAC1 (0.81) | HDAC1HDAC2SCDHDAC3HDAC8 | |
| SCHEMBL2733826 | 0.85 | HDAC1 (0.79) | HDAC1HDAC2HDAC3HDAC8NCOR2 | |
| SCHEMBL211848 | 0.85 | HDAC1 (0.56) | HDAC1NPC1RAB9AMCL1MMP13 | |
| SCHEMBL4972632 | 0.85 | HDAC1 (0.78) | HDAC1NPC1RAB9AHDAC2HDAC3 | |
| SCHEMBL5793017 | 0.84 | NPC1 (0.58) | HDAC1NPC1RAB9AMCL1MMP13 | |
| SCHEMBL213443 | 0.83 | HDAC1 (0.76) | HDAC1HDAC2HDAC3HDAC8NCOR2 | |
| SCHEMBL1064488 | 0.83 | HDAC1 (1.00) | HDAC1NPC1RAB9ASCD | |
| SCHEMBL5001543 | 0.80 | RIPK1 (0.63) | NPC1RAB9AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL211854 | 0.80 | HDAC1 (0.78) | HDAC1HDAC2SCDHDAC3HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| EP-1735319-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2006-12-27 | — | — | EP | disclosed |
| US-20050245518-A1 | Antiproliferative agents | METHYLGENE, INC. | 2005-11-03 | — | — | US | disclosed |
| WO-2005092899-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885NPC1 1293/4885RAB9A 3036/4885 |
| US-20050245518-A1 | Antiproliferative agents | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885NPC1 1178/4885RAB9A 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.